Illumina Pins 2026 Growth On Clinical Sequencing As Research Spending Stays Constrained

Limited China Imports Resume But Broader Market Access Remains Unresolved

 
• By Shubham Singh
  
Responding to questions from JPMorgan analyst Casey Woodring, Thaysen sketched out a turbulent 2025 marked by proposed US government funding cuts, geopolitical pressures, and regulatory challenges in China.

More from J.P. Morgan

More from Conferences